… Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly … psoriasis, Crohn's
disease and ulcerative colitis were … : detection of tumor necrosis factor α in two patients with early …

… Psoriasis is a common, chronic, immunemediated, and recurrent … The expressions of
tumor necrosis factor-α (TNF-α), … , and PBMCs were then isolated with a ficoll density gradient …

… Knee osteoarthritis (KOA) is a chronic retrogressive knee … -6 (IL-6), tumor necrosis factor-α
(TNF-α), prostaglandin E2α (PGE2α) … Safety Estimation The symptoms and physical signs of …

… agents targeting inflammatory factors, tumor necrosis factor-α, … in treating moderate-to-severe
psoriasis. However, with the … and safety of guselkumab in patients with psoriasis who have …

… Dynamic changes of serum tumor necrosis factor-α, interleukin-10 in rats with acute liver
failure and the hepatoprotective mechanism of tumor necrosis factor-α monoclonal antibody[J]. …

… agents in the treatment of psoriasis is reviewed in this paper. … response to anti-tumor necrosis
factor therapy in psoriasis: a … Efficacy and safety of ustekinumabꎬ a human interleukin-12/ …

… , particularly for patients with moderate to severe psoriasis and/or psoriatic ar-thritis … are
poorly tolerated. Biologics can bring lasting efficacy, long-term safety and ease of use for patients…

… Abstract: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease … or tumor
necrosis factor-α inhibitors. In this review, mechanism of action, clinical efficacy and safety of …

… Psoriasis: which therapy for which patient: psoriasis comorbidities … antibodies inhibiting
human tumor necrosis factor receptor 1. The … Safety and efficacy of multiple ascending doses of …

… Adalimumab: long-term safety in 23 458 patients from global … ankylosing spondylitis, psoriatic
arthritis, psoriasis and Crohn's … response to tumor necrosis factor-α blockers in patients with …